Skip to main content

Table 2 Height/length, weight, and weight for height between the two groups on the GEE models

From: Effects of early recombinant human growth hormone treatment in young Chinese children with Prader–Willi syndrome

 

B

95%Cl

P value

Height/length SDS

Later treatment group

−1.50

(−2.13, −0.88)

 < 0.001

2 years old (early treatment group)

0.17

(−0.07, 0.41)

0.165

3 years old (early treatment group)

0.30

(0.02, 0.58)

0.037

4 years old (early treatment group)

0.49

(0.17, 0.82)

0.003

Later treatment group × 2 years old

0.52

(0.02, 1.01)

0.042

Later treatment group × 3 years old

0.76

(0.27, 1.26)

0.003

Later treatment group × 4 years old

0.88

(0.30, 1.45)

0.003

Weight SDS

Later treatment group

−0.94

(−1.52, −0.37)

0.001

2 years old (early treatment group)

0.48

(0.23, 0.73)

 < 0.001

3 years old (early treatment group)

0.88

(0.60, 1.16)

 < 0.001

4 years old (early treatment group)

1.28

(0.92, 1.64)

 < 0.001

Later treatment group × 2 years old

0.11

(−0.36, 0.57)

0.648

Later treatment group × 3 years old

0.66

(−0.01, 1.33)

0.052

Later treatment group × 4 years old

1.18

(0.37, 1.98)

0.004

Weight for height SDS

Later treatment group

−0.33

(−0.97, 0.32)

0.324

2 years old (early treatment group)

0.50

(0.14, 0.86)

0.006

3 years old (early treatment group)

1.02

(0.63, 1.40)

 < 0.001

4 years old (early treatment group)

1.47

(1.00, 1.95)

 < 0.001

Later treatment group × 2 years old

−0.15

(−0.77, 0.48)

0.652

Later treatment group × 3 years old

0.47

(−0.38, 1.32)

0.281

Later treatment group × 4 years old

1.16

(0.14, 2.19)

0.026

  1. The reference group for each variable is early treatment group, 1 year old (early treatment group), early treatment group × age